NASDAQ · BRKR
Bruker Corporation
Healthcare · Medical - Devices
$64.18▲ 0.28% ($0.18)at close
As of 4:00 PM ET
Market cap
$9.77B
P/E
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Enterprise value of $1.15B does not cover net debt, preferred stock and minority interest of $1.75B, so equity value is negative and no fair value per share can be shown. The projected cash flows are positive; the shortfall is in the equity bridge, not the forecast. This engine cannot separate captive-finance or other non-operating borrowings from operating debt.
Price vs. estimate range
Assumption scenarios, not confidence intervals
Bull $11.73; price used $64.18
Bull $11.73; price used $64.18
- 10-yr revenue CAGR
- 5.9%
- Ending operating margin
- 3.6%
- Discount rate
- 10.5%
USD · TTM ending Jun 30, 2026 · Price used $64.18 · Price Sep 25, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 108.51% over the last year. Revenue grew 1.65% over the trailing twelve months. Operating margin moved from 5.34% to 3.61%. Free cash flow grew 90.47% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 3.61%. A decisive move in revenue — currently up 1.65% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
17
Buy
14
Hold
2
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 2, 2026
Q4 FY26 · EPS est $0.42 · Revenue est $867.38M
View
Institutional Sentiment
Bruker Corporation · BRKR
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.